HitGen and Morphic Therapeutic extend drug discovery research collaboration to identify small molecule leads against targets

HitGen Inc., Morphic Therapeutic | July 06, 2020

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compounds that were exclusively licensed to Morphic.

Under the terms of the extended agreement, HitGen will use its platform technology, based on the design, synthesis and interrogation by selection of DELs to discover ligands for targets of interest to Morphic. Morphic will pay an assignment fee to HitGen in exchange for exclusive development and commercialization rights to compounds that achieve the criteria of the collaboration.

Spotlight

FranceMed Pharma Corporate Video.

Spotlight

FranceMed Pharma Corporate Video.

Related News

PHARMA TECH

Prescryptive Health Launches Comprehensive Pharmacy Management Platform to Expand the Scope of Community Pharmacists

Prescryptive Health | October 06, 2021

Healthcare technology company Prescryptive Health today announced that MyRx PRO is now operational nationwide. The pharmacy management platform allows pharmacists to digitize their business with new revenue opportunities through profitable clinical services and a deeper patient engagement experience. Today we change the course of the community pharmacist, by empowering them to expand their business and meet new customers through new services, all on our secure platform. Pharmacists are central to community health, and we are proud to offer a system to help them transform for the digital age. - Chris Blackley, CEO of Prescryptive Health At the core of MyRx PRO are turn-key clinical services, which build in patient engagement, inventory management, reporting, and billing all on one platform. This includes critical COVID-19 care—testing, vaccinations, and monoclonal antibody treatment—and flu services for the ongoing public health crisis. MyRx PRO pharmacists already on the platform had a lift in annual revenue up to 25%; by offering relevant services, pharmacists can grow their business while providing the healthcare needed in their local communities. New patients find these services through Prescryptive's patient-friendly mobile solution, MyRx.io. I'm getting new patients at my counter every day thanks to Prescryptive, MyRx PRO allows me to offer more services efficiently so I can focus on what matters most: patient care. - Vincent Chiffy, owner of Parkway Drugs in Utica, NY. MyRx PRO also features SmartPRICE™ with AI-driven intelligent pricing capabilities and a solution for cash-paying customers. Unlike popular cash discount cards, SmartPRICE™ saves patients up to 80% on prescriptions without exorbitant fees charged to local pharmacies by third parties. MyRx PRO is available nationwide today, with new clinical services added continually. About Prescryptive Health Prescryptive Health is a healthcare technology company delivering solutions that empower consumers. Prescryptive's secure, mobile-first products connect consumers, pharmacists, and employers, ultimately providing people with the information they need to make informed decisions and take control of their health.

Read More

Medidata, TriNetX, and Datavant Partner to Enable Seamless Integration of Real-World Data in Clinical Development

Medidata | October 30, 2020

Medidata, a Dassault Systèmes company, TriNetX, and Datavant announced a partnership that will accelerate the use of real-world data (RWD) to power clinical research. Linking RWD, which are data not collected during the specific context of the trial, can help improve understanding of the long-term safety and efficacy of new therapies. This partnership will enable users of Medidata’s end-to-end clinical research platform to securely link their clinical data with patient consent to de-identified patient data without unblinding the study. The solution leverages Datavant’s Patient Key technology and data ecosystem, as well as RWD from TriNetX’s global network of healthcare organizations who participate in this program

Read More

BUSINESS INSIGHTS

Triastek and Siemens Announced a Strategic Partnership to Advance the Pharmaceutical Industry's Digital Transformation

Triastek, Inc | March 21, 2022

Triastek, Inc. and Siemens Ltd., China, have agreed to collaborate on digital technologies for the worldwide pharmaceutical business. Triastek's industry-leading 3D printing and digital pharmaceutical technologies, combined with Siemens' worldwide experience in automation and digitalization, should result in unique and disruptive pharmaceutical research and production solutions. Pharmaceutical companies have been encouraged to modernize their manufacturing processes by adopting continuous manufacturing processes and digital technologies by regulatory agencies such as the US FDA (Food and Drug Administration), the European Medicines Agency and China's NMPA. Triastek is aggressively applying the continuous manufacturing strategy in combination with new digital technologies to simplify and optimize their production processes and products. When these advances are combined with Siemens' digitalization and automation skills, regulatory agencies will be able to meet their goals of reducing pharmaceutical product quality concerns, lowering manufacturing costs, and increasing patient access to high-quality medications. Triastek and Siemens will collaborate to solve pharmaceutical industry demands and enhance patient outcomes using their respective technology advantages, strengths, and capabilities. Triastek's proprietary pharmaceutical MED® (Melt Extrusion Deposition) 3D printing platform technology for R&D and mass production will accelerate product R&D and facilitate continuous manufacturing approaches, paperless production, real-time product release, equipment, and facility maintenance combined with Siemens' advanced automation and digital technologies. These advances are intended to increase throughput on the manufacturing line while maintaining the greatest product quality. Finally, Triastek wants to build an intelligent pharmaceutical production center in conjunction with Siemens, where virtual laboratories, smart factories, and digital twin technologies will be integrated into every element of pharmaceutical operations. Triastek, founded in 2015, is now in the mass manufacturing and commercial development stages. Triastek announced its Era 2.0 Open Strategy in October 2021, which outlines a goal to market its patented MED® 3D printing technology via partnerships with global pharmaceutical firms and suppliers. Triastek delivers digital product R&D and a unique manufacturing platform based on its Open Strategy and cooperation, allowing business partners to use and integrate Triastek technology into their operations, from early medication discovery through commercial production. "This strategic collaboration has broadened the possibilities of pharmaceutical digitalization. Triastek's MED® 3D printing technology represents a new digital pharmaceutical technology, building the foundation for a digital pharma future. MED® 3D printing represents a novel drug R&D paradigm, from product development through product launch, while introducing new models to manage production and supply. Triastek will make this open platform available to digital technology providers to jointly advance the Pharma 4.0 initiative, serving our greater vision of transforming the pharmaceutical industry's future." Dr. Senping Cheng, Founder, and CEO of Triastek Senior Vice President and General Manager of sales region east of digital industries of Siemens Ltd., China, Mr. Jinsong Zhang, also commented on this partnership: "Siemens' strategic cooperation with Triastek builds win-win cooperation of a digital solution provider leader and a 3D printing pharmaceutical leader. Siemens has rich 3D printing experiences and a full spectrum of digital solutions for manufacturing transformation. I believe the fusion of 3D printing technology with pharmaceutical digitalization establishes a new paradigm, which unifies R&D and production, and advances the end-to-end model from demand to delivery. The partnership will help Triastek to accelerate digital ph.

Read More